This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

ONLINE REGISTRATION CLOSES IN:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Jean-Philippe Bürckert, Ph.D.
Director of Bioinformatics at Charles River Laboratories

Profile

Jean-Philippe Burckert is a computational antibody engineer and bioinformatician with over a decade of experience in applied informatics and data science in the field of adaptive immunology.

He began his career as a chemist graduating from the Kaiserslautern University in Germany, working on small molecule drug discovery against fungal grape vine disease (ESCA). Afterwards, he obtained his PhD from the Luxembourg Institute of Health developing computational and laboratory methods to decipher adaptive immune responses in the context of rational vaccine design, as well as antibody discovery using the transgenic humanized OmniRatTM model.

In 2018, Jean-Philippe joined the Belgium consulting firm BISC Global to establish their US based operations out of Boston, MA, gathering broad knowledge in the fields of computational immunology and bioinformatics. He consulted with over a dozen pharma and biotech companies before joining Distributed Bio as Director of Computational Immunology. He led a team of seven scientists supporting all efforts of antibody discovery and algorithm development, resulting in two record breaking years and ultimately, the successful acquisition of Distributed Bio by Charles River Laboratories at the end of 2020. Now at Charles River Laboratories, Dr. Burckert functions as Director of Bioinformatics for large molecule discoveries heading the antibody engineering and R&D efforts in South San Francisco.

Agenda Sessions

  • Where First-in-Class Meets Best-in-Class: How Optimal Strategies and Exceptional Libraries Deliver Drug Ready Candidates

    11:20